A Phase 3, Randomized, Multicenter, Double-masked Study to Compare the Ocular Safety, Tolerability, and Efficacy of ISV-305 (0.1% Dexamethasone in DuraSite® 2) to DuraSite 2 Vehicle for the Treatment of Inflammation and Pain Associated With Cataract Surgery
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 22 Oct 2019
Price : $35 *
At a glance
- Drugs Dexamethasone (Primary)
- Indications Inflammation; Pain
- Focus Therapeutic Use
- Sponsors InSite Vision
- 17 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 12 Sep 2019 Planned End Date changed from 1 Dec 2019 to 1 Mar 2020.
- 12 Sep 2019 Planned primary completion date changed from 1 Sep 2019 to 1 Dec 2019.